TY - JOUR
T1 - Periampullary cancers
T2 - Are there differences?
AU - Sarmiento, J. M.
AU - Nagorney, D. M.
AU - Sarr, M. G.
AU - Farnell, M. B.
PY - 2001
Y1 - 2001
N2 - Our review supports the clinical impression that periampullary cancers vary in outcome after resection. Overall survival after pancreaticoduodenectomy is greatest for patients with ampullary and duodenal cancers, intermediate for patients with bile duct cancer, and least for patients with pancreatic cancer. Moreover, survival for each tumor stage is greater for nonpancreatic periampullary cancers than for pancreatic cancers. Invasion of the pancreas by nonpancreatic periampullary cancers is a major factor adversely affecting survival. Recent data suggest that inherent differences in tumor biology rather than embryologic, anatomic, or histologic factors probably account for these differences in survival. Finally, although pancreaticoduodenectomy remains the procedure of choice for resectable periampullary cancers, further increases in survival will likely evolve through more effective neoadjuvant or adjuvant therapies rather than modifications in the surgical approach.
AB - Our review supports the clinical impression that periampullary cancers vary in outcome after resection. Overall survival after pancreaticoduodenectomy is greatest for patients with ampullary and duodenal cancers, intermediate for patients with bile duct cancer, and least for patients with pancreatic cancer. Moreover, survival for each tumor stage is greater for nonpancreatic periampullary cancers than for pancreatic cancers. Invasion of the pancreas by nonpancreatic periampullary cancers is a major factor adversely affecting survival. Recent data suggest that inherent differences in tumor biology rather than embryologic, anatomic, or histologic factors probably account for these differences in survival. Finally, although pancreaticoduodenectomy remains the procedure of choice for resectable periampullary cancers, further increases in survival will likely evolve through more effective neoadjuvant or adjuvant therapies rather than modifications in the surgical approach.
UR - http://www.scopus.com/inward/record.url?scp=0034973988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034973988&partnerID=8YFLogxK
U2 - 10.1016/S0039-6109(05)70142-0
DO - 10.1016/S0039-6109(05)70142-0
M3 - Article
C2 - 11459270
AN - SCOPUS:0034973988
SN - 0039-6109
VL - 81
SP - 543
EP - 555
JO - Surgical Clinics of North America
JF - Surgical Clinics of North America
IS - 3
ER -